Neuroactive Steroids for Antidepressant-Induced Sexual Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating sexual dysfunction, particularly treatment-induced sexual dysfunction, often result in significant side effects and do not effectively address the underlying issues, especially for patients taking antidepressants.
Innovation Solution
Administration of Compound (1) or Compound (2), which are neuroactive steroids acting as positive allosteric modulators of GABAA receptors, to treat sexual dysfunction and related CNS disorders with reduced or no side effects, including a specific dosing regimen and assessment using the Changes in Sexual Functioning Questionnaire-14.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressants are administered to treat CNS disorders, then therapeutic effect is improved, but sexual dysfunction side effects worsen
Solution Approach 1:
The patent introduces a second medication specifically for treating sexual dysfunction side effects as an intermediary solution. This mediator addresses the harmful sexual dysfunction caused by antidepressants without requiring discontinuation of the primary antidepressant therapy, thereby maintaining both therapeutic efficacy and sexual function
Solution Approach 2:
The patent explores dose reduction of antidepressants as a parameter change strategy. By adjusting the dosage parameter, the patent attempts to maintain sufficient therapeutic effect while reducing the intensity of sexual dysfunction side effects, though this may compromise complete treatment of the underlying CNS disorder
2Object-generated harmful factors
If dose reduction is applied to reduce sexual dysfunction, then side effects are reduced, but therapeutic effect worsens
Solution Approach 1:
The patent introduces a second medication specifically for treating sexual dysfunction side effects as an intermediary solution. This mediator addresses the harmful sexual dysfunction caused by antidepressants without requiring discontinuation of the primary antidepressant therapy, thereby maintaining both therapeutic efficacy and sexual function
3Object-generated harmful factors
If medication is added to treat sexual adverse effects, then sexual function is improved, but treatment complexity worsens
Solution Approach 1:
The patent introduces a second medication specifically for treating sexual dysfunction side effects as an intermediary solution. This mediator addresses the harmful sexual dysfunction caused by antidepressants without requiring discontinuation of the primary antidepressant therapy, thereby maintaining both therapeutic efficacy and sexual function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds help maintain sexual function in patients with mood disorders and those receiving chemical psychotherapy, reducing treatment-emergent sexual dysfunction without significant impairment, as shown by stable or improved CSFQ-14 scores over time.
Implementation Method 1
Administration of Compound (1) or Compound (2), which are neuroactive steroids acting as positive allosteric modulators of GABAA receptors, to treat sexual dysfunction and related CNS disorders
Data Source
AI summary
This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.